Medicine Online
Any medical inquiries? Search MOL for answers:
MEDICAL DRUGS
Home > Medical Drugs > Drugs beginning with D > DuoNeb(Ipratropium Bromide 0.5 mg/Albuterol Sulfate 3.0 mg)Inhalation Solution
Medical References
Diseases & Conditions
Women's Health
Mental Health
Men's Health
Healthy Choice News
Site Map Links
Medical Tips
Attention, chocolate lovers: You may not be able to help yourselves. Swiss and British scientists have linked the widespread love of chocolate to a chemical "signature" that may be programmed into our metabolic systems.
Read more health news

DuoNeb®
(Ipratropium Bromide 0.5 mg/Albuterol Sulfate 3.0 mgEquivalent to 2.5 mg albuterol base)
Inhalation Solution

DESCRIPTION

The active components in DuoNeb® Inhalation Solution are albuterol sulfate and ipratropium bromide.

Albuterol sulfate, is a salt of racemic albuterol and a relatively selective β2-adrenergic bronchodilator chemically described as α1-[(tert-butylamino)methyl]-4-hydroxy-m-xylene-α, α'-diol sulfate (2:1) (salt). It has a molecular weight of 576.7 and the empirical formula is (C13H21NO3)2•H2SO4. It is a white crystalline powder, soluble in water and slightly soluble in ethanol. The World Health Organization recommended name for albuterol base is salbutamol.

Ipratropium bromide is an anticholinergic bronchodilator chemically described as 8-azoniabicyclo [3.2.1]-octane, 3-(3-hydroxy-1-oxo-2-phenylpropoxy)-8methyl-8-(1-methylethyl)-, bromide, monohydrate (endo, syn)-, (±)-; a synthetic quaternary ammonium compound, chemically related to atropine. It has a molecular weight of 430.4 and the empirical formula is C20H30BrNO3•H2O. It is a white crystalline substance, freely soluble in water and lower alcohols, and insoluble in lipophilic solvents such as ether, chloroform, and fluorocarbons.

Each 3 mL vial of DuoNeb contains 3.0 mg (0.1%) of albuterol sulfate (equivalent to 2.5 mg (0.083%) of albuterol base) and 0.5 mg (0.017%) of ipratropium bromide in an isotonic, sterile, aqueous solution containing sodium chloride, hydrochloric acid to adjust to pH 4, and edetate disodium, USP (a chelating agent).

DuoNeb is a clear, colorless solution. It does not require dilution prior to administration by nebulization. For DuoNeb Inhalation Solution, like all other nebulized treatments, the amount delivered to the lungs will depend on patient factors, the jet nebulizer utilized, and compressor performance. Using the Pari-LC-Plus™ nebulizer (with face mask or mouthpiece) connected to a PRONEB™ compressor system, under in vitro conditions, the mean delivered dose from the mouth piece (% nominal dose) was approximately 46% of albuterol and 42% of ipratropium bromide at a mean flow rate of 3.6 L/min. The mean nebulization time was 15 minutes or less. DuoNeb should be administered from jet nebulizers at adequate flow rates, via face masks or mouthpieces (see DOSAGE AND ADMINISTRATION).

CLINICAL PHARMACOLOGY

DuoNeb Inhalation Solution is a combination of the β2-adrenergic bronchodilator, albuterol sulfate, and the anticholinergic bronchodilator, ipratropium bromide.

Albuterol sulfate

Ipratropium bromide

DuoNeb®

INDICATIONS AND USAGE

DuoNeb is indicated for the treatment of bronchospasm associated with COPD in patients requiring more than one bronchodilator.

CONTRAINDICATIONS

DuoNeb is contraindicated in patients with a history of hypersensitivity to any of its components, or to atropine and its derivatives.

WARNINGS

Paradoxical Bronchospasm

In the clinical study of DuoNeb, paradoxical bronchospasm was not observed. However, paradoxical bronchospasm has been observed with both inhaled ipratropium bromide and albuterol products and can be life-threatening. If this occurs, DuoNeb should be discontinued immediately and alternative therapy instituted.

Do Not Exceed Recommended Dose

Fatalities have been reported in association with excessive use of inhaled products containing sympathomimetic amines and with the home use of nebulizers.

Cardiovascular Effect

DuoNeb, like other beta adrenergic agonists, can produce a clinically significant cardiovascular effect in some patients as measured by pulse rate, blood pressure, and/or symptoms. Although such effects are uncommon for DuoNeb at recommended doses, if they occur, the drug may need to be discontinued. In addition, beta agonists have been reported to produce ECG changes, such as flattening of the T-wave, prolongation of the QTc interval, and ST segment depression. The clinical significance of these findings is unknown. Therefore, DuoNeb, like other sympathomimetic amines, should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension.

Immediate Hypersensitivity Reactions

Immediate hypersensitivity reactions to albuterol and/or ipratropium bromide may occur after the administration of DuoNeb as demonstrated by rare cases of urticaria, angioedema, rash, pruritus, oropharyngeal edema, bronchospasm, and anaphylaxis.

PRECAUTIONS

General

Information for Patients

The action of DuoNeb should last up to 5 hours. DuoNeb should not be used more frequently than recommended. Patients should be instructed not to increase the dose or frequency of DuoNeb without consulting their healthcare provider. If symptoms worsen, patients should be instructed to seek medical consultation.

Patients must avoid exposing their eyes to this product as temporary papillary dilation, blurred vision, eye pain, or precipitation or worsening of narrow-angle glaucoma may occur, and therefore proper nebulizer technique should be assured, particularly if a mask is used.

If a patient becomes pregnant or begins nursing while on DuoNeb, they should contact their healthcare provider about use of DuoNeb.

See the illustrated Patient's Instruction for Use in the product package insert.

Drug Interactions

Carcinogenesis, Mutagenesis, Impairment of Fertility

Pregnancy

TERATOGENIC EFFECTS

Labor and Delivery

Oral albuterol sulfate has been shown to delay preterm labor in some reports. Because of the potential of albuterol to interfere with uterine contractility, use of DuoNeb during labor should be restricted to those patients in whom the benefits clearly outweigh the risks.

Nursing Mothers

It is not known whether the components of DuoNeb are excreted in human milk. Although lipid-insoluble quaternary bases pass into breast milk, it is unlikely that ipratropium bromide would reach the infant to an important extent, especially when taken as a nebulized solution. Because of the potential for tumorigenicity shown for albuterol sulfate in some animals, a decision should be made whether to discontinue nursing or discontinue DuoNeb, taking into account the importance of the drug to the mother.

Pediatric Use

The safety and effectiveness of DuoNeb in patients below 18 years of age have not been established.

Geriatric Use

Of the total number of subjects in clinical studies of DuoNeb, 62 percent were 65 and over, while 19 percent were 75 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

ADVERSE REACTIONS

Adverse reaction information concerning DuoNeb was derived from the 12-week controlled clinical trial.

ADVERSE EVENTS OCCURRING IN ≥ 1% OF ≥ 1 TREATMENT GROUP(S) AND WHERE THE COMBINATION TREATMENT SHOWED THE HIGHEST PERCENTAGE
Body System
COSTART Term
Albuterol
n (%)
Ipratropium
n (%)
DuoNeb
n (%)
NUMBER OF PATIENTS761754765
N (%) Patients with AE327 (43.0)329 (43.6)367 (48.0)
BODY AS A WHOLE
  Pain8 (1.1)4 (0.5)10 (1.3)
  Pain chest11 (1.4)14 (1.9)20 (2.6)
DIGESTIVE
  Diarrhea5 (0.7)9 (1.2)14 (1.8)
  Dyspepsia7 (0.9)8 (1.1)10 (1.3)
  Nausea7 (0.9)6 (0.8)11 (1.4)
MUSCULO-SKELETAL
  Cramps leg8 (1.1)6 (0.8)11 (1.4)
RESPIRATORY
  Bronchitis11 (1.4)13 (1.7)13 (1.7)
  Lung Disease36 (4.7)34 (4.5)49 (6.4)
  Pharyngitis27 (3.5)27 (3.6)34 (4.4)
  Pneumonia7 (0.9)8 (1.1)10 (1.3)
UROGENITAL
  Infection urinary tract3 (0.4)9 (1.2)12 (1.6)

Additional adverse reactions reported in more than 1% of patients treated with DuoNeb included constipation and voice alterations.

In the clinical trial, there was a 0.3% incidence of possible allergic-type reactions, including skin rash, pruritus, and urticaria.

Additional information derived from the published literature on the use of albuterol sulfate and ipratropium bromide singly or in combination includes precipitation or worsening of narrow-angle glaucoma, acute eye pain, blurred vision, paradoxical bronchospasm, wheezing, exacerbation of COPD symptoms, drowsiness, aching, flushing, upper respiratory tract infection, palpitations, taste perversion, elevated heart rate, sinusitis, back pain and sore throat.

OVERDOSAGE

The effects of overdosage with DuoNeb are expected to be related primarily to albuterol sulfate, since ipratropium bromide is not well-absorbed systemically after oral or aerosol administration. The expected symptoms with overdosage are those of excessive beta-adrenergic stimulation and/or occurrence or exaggeration of symptoms such as seizures, angina, hypertension or hypotension, tachycardia with rates up to 200 beats per minute, arrhythmia, nervousness, headache, tremor, dry mouth, palpitation, nausea, dizziness, fatigue, malaise, insomnia, and exaggeration of pharmacological effects uled in ADVERSE REACTIONS. Hypokalemia may also occur. As with all sympathomimetic aerosol medications, cardiac arrest and even death may be associated with abuse of DuoNeb. Treatment consists of discontinuation of DuoNeb together with appropriate symptomatic therapy. The judicious use of a cardioselective beta-receptor blocker may be considered, bearing in mind that such medication can produce bronchospasm. There is insufficient evidence to determine if dialysis is beneficial for overdosage of DuoNeb.

The oral median lethal dose of albuterol sulfate in mice is greater than 2000 mg/kg (approximately 540 times the maximum recommended daily inhalation dose of DuoNeb on a mg/m2 basis). The subcutaneous median lethal dose of albuterol sulfate in mature rats and small young rats is approximately 450 and 2000 mg/kg respectively (approximately 240 and 1100 times the maximum recommended daily inhalation dose of DuoNeb on a mg/m2 basis, respectively). The inhalation median lethal dose has not been determined in animals. The oral median lethal dose of ipratropium bromide in mice, rats and dogs is greater than 1000 mg/kg, approximately 1700 mg/kg and approximately 400 mg/kg, respectively (approximately 1400, 4600, and 3600 times the maximum recommended daily inhalation dose in adults on a mg/m2 basis, respectively).

DOSAGE AND ADMINISTRATION

The recommended dose of DuoNeb is one 3 mL vial administered 4 times per day via nebulization with up to 2 additional 3 mL doses allowed per day, if needed. Safety and efficacy of additional doses or increased frequency of administration of DuoNeb beyond these guidelines has not been studied and the safety and efficacy of extra doses of albuterol sulfate or ipratropium bromide in addition to the recommended doses of DuoNeb have not been studied.

The use of DuoNeb can be continued as medically indicated to control recurring bouts of bronchospasm. If a previously effective regimen fails to provide the usual relief, medical advice should be sought immediately, as this is often a sign of worsening COPD, which would require reassessment of therapy.

A Pari-LC-Plus™ nebulizer (with face mask or mouthpiece) connected to a PRONEB™ compressor was used to deliver DuoNeb to each patient in one U.S. clinical study. The safety and efficacy of DuoNeb delivered by other nebulizers and compressors have not been established.

DuoNeb should be administered via jet nebulizer connected to an air compressor with an adequate air flow, equipped with a mouthpiece or suitable face mask.

HOW SUPPLIED

DuoNeb is supplied as a 3-mL sterile solution for nebulization in sterile low-density polyethylene unit-dose vials. Store in pouch until time of use. Supplied in cartons as uled below.

NDC 49502-672-30          30 vials per carton/5 vials per foil pouch
NDC 49502-672-60          60 vials per carton/5 vials per foil pouch
NDC 49502-672-31          30 vials per carton/1 vial per foil pouch

Store between 2°C and 30°C (36°F and 86°F). Protect from light.

DuoNeb is a registered trademark of Dey, L.P.

03-485-26

JAN 06

DuoNeb®
(Ipratropium Bromide 0.5 mg/Albuterol Sulfate 3.0 mgEquivalent to 2.5 mg albuterol base)
Inhalation Solution


Patient's Instructions for Use

Read this patient information completely every time your prescription is filled as information may have changed. Keep these instructions with your medication as you may want to read them again.

DuoNeb should only be used under the direction of a physician.Your physician and pharmacist have more information about DuoNeb and the condition for which it has been prescribed. Contact them if you have additional questions.


Storing your Medicine

Store DuoNeb between 2°C and 30°C (36°F and 86°F). Vials should be protected from light before use, therefore, keep unused vials in the foil pouch or carton. Do not use after the expiration (EXP) date printed on the carton.


Dose

DuoNeb is supplied as a single-dose, ready-to-use vial containing 3 mL of solution. No mixing or dilution is needed. Use one new vial for each nebulizer treatment.

FOLLOW THESE DIRECTIONS FOR USE OF YOUR NEBULIZER/COMPRESSOR OR THE DIRECTIONS GIVEN BY YOUR HEALTHCARE PROVIDER. A TYPICAL EXAMPLE IS SHOWN BELOW.


Instructions for Use

  • Remove one vial from the foil pouch. Place remaining vials back into pouch for storage.
  • Twist the cap completely off the vial and squeeze the spans into the nebulizer reservoir (Figure 1).
  • 3.Connect the nebulizer to the mouthpiece or face mask (Figure 2).
  • 4.Connect the nebulizer to the compressor.
  • 5.Sit in a comfortable, upright position; place the mouthpiece in your mouth (Figure 3) or put on the face mask (Figure 4); and turn on the compressor.
  • 6.Breathe as calmly, deeply and evenly as possible through your mouth until no more mist is formed in the nebulizer chamber (about 5-15 minutes). At this point, the treatment is finished.
  • 7.Clean the nebulizer (see manufacturer's instructions).

03-485-26

JAN 06